Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting
08 févr. 2022 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase
29 déc. 2021 08h30 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus
08 déc. 2021 08h00 HE
|
Palisade Bio, Inc.
Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio’s Patent Portfolio The Company Continues to Advance LB1148 for Key Indications After LB1148 Topline Efficacy Results from...
Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035
30 nov. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations
23 nov. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic...
Palisade Bio Reports Third Quarter Financial Results
15 nov. 2021 07h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help...
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders
22 oct. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharma company advancing oral therapies that help patients with acute and chronic...
Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
09 sept. 2021 08h30 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Palisade Bio Reports Second Quarter Financial Results and Provides Business Update
24 août 2021 08h15 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic...
Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center
20 août 2021 09h25 HE
|
Palisade Bio, Inc.
$5.2M invested at $3.45 stock priceFunds to be used to advance clinical development of LB1148Investment driven by Phase 2 clinical data that the medical center believes may lead to LB1148 being used...